• Publications
  • Influence
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
TLDR
The clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells, is reported on. Expand
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate
TLDR
T cells engaged by blinatumomab seem capable of eradicating chemotherapy-resistant tumor cells that otherwise cause clinical relapse in patients with MRD-positive B-lineage ALL after intensive chemotherapy. Expand
Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing
TLDR
It is proposed that PHDs and FIH-1 form an oxygen sensor cascade of distinct subcellular localisation, which results in the decreased ability of HIF-1 to bind to the transcriptional coactivator p300/CBP. Expand
Cutting Edge: Neutrophil Granulocyte Serves as a Vector for Leishmania Entry into Macrophages1
TLDR
The data indicate that Leishmania can misuse granulocytes as a “Trojan horse” to enter their final host cells “silently” and unrecognized. Expand
Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum
TLDR
It is reported that the virulent inoculum of Leishmania promastigotes contains a high ratio of annexin A5-binding apoptotic parasites, which enable the intracellular survival of the viable parasites. Expand
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
TLDR
In this phase I study of relapsed/refractory NHL, continuous infusion with CD19-targeted immunotherapy blinatumomab at various doses and schedules was feasible, with an MTD of 60 μg/m(2)/day that showed antilymphoma activity. Expand
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
TLDR
The response of lymphocytes in leukemic patients to continuous infusion of blinatumomab helps to better understand the mode of action of this and other globally T cell-engaging Abs. Expand
Immobilized Immune Complexes Induce Neutrophil Extracellular Trap Release by Human Neutrophil Granulocytes via FcγRIIIB and Mac-1
TLDR
The present study shows for the first time that iICs induce NET formation, and concludes that NETs contribute to pathology in autoimmune inflammatory disorders associated with surface-bound ICs. Expand
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
TLDR
It is concluded that blinatumomab can induce long-lasting complete remission in B-lineage ALL patients with persistent or recurrent MRD and of the subgroup of 6 Philadelphia chromosome-negative MRD responders with no further therapy after blinumomab, 4 are in ongoing hematologic and molecular remission. Expand
Platelets and inflammation
  • M. Klinger
  • Biology, Medicine
  • Anatomy and Embryology
  • 26 June 1997
TLDR
The connection between IgE and platelets, besides the platelet-induced eosinophil infiltration, offers a functional basis for the involvement of platelets in allergic processes, particular in the skin and the airways. Expand
...
1
2
3
4
5
...